Vivoryon Therapeutics NV (FRA:05Y) ROE % Adjusted to Book Value: -19.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:05Y Vivoryon Therapeutics NV FRA:05Y
38 GF Score
Price €1.17
! 2 Warning Signs
View Full Analysis

What is Vivoryon Therapeutics NV ROE % Adjusted to Book Value?

Vivoryon Therapeutics NV FRA:05Y -0.43% 38 ROE % Adjusted to Book Value is -19.00% as of Dec. 2025. GuruFocus rates FRA:05Y with a GF Score™ of 38/100. The stock has 2 warning signs investors should review.

Vivoryon Therapeutics NV's ROE % for the quarter that ended in Dec. 2025 was -170.97%. Vivoryon Therapeutics NV's PB Ratio for the quarter that ended in Dec. 2025 was 9.00. Vivoryon Therapeutics NV's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -19.00%.

Vivoryon Therapeutics NV ROE % Adjusted to Book Value Related Terms

Vivoryon Therapeutics NV ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Vivoryon Therapeutics NV's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivoryon Therapeutics NV ROE % Adjusted to Book Value Chart

Vivoryon Therapeutics NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.57 -13.91 -12.94 -18.33 -15.61

Vivoryon Therapeutics NV Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.53 -39.86 -19.52 -16.32 -19.00

FRA:05Y vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Vivoryon Therapeutics NV's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vivoryon Therapeutics NV ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vivoryon Therapeutics NV's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Vivoryon Therapeutics NV's ROE % Adjusted to Book Value falls into.


FRA:05Y
38GF Score
Vivoryon Therapeutics NV FRA:05Y
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivoryon Therapeutics NV ROE % Adjusted to Book Value Calculation

Vivoryon Therapeutics NV's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-140.45% / 9.00
=-15.61%

Vivoryon Therapeutics NV's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-170.97% / 9.00
=-19.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -19.00% mean?
Vivoryon Therapeutics NV (FRA:05Y) has a ROE % Adjusted to Book Value of -19.00% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Vivoryon Therapeutics NV and its competitors.
Is Vivoryon Therapeutics NV's ROE % Adjusted to Book Value too high?
Vivoryon Therapeutics NV's current ROE % Adjusted to Book Value is -19.00%. Overall, Vivoryon Therapeutics NV has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Vivoryon Therapeutics NV's ROE % Adjusted to Book Value compare to VRTX and REGN?
Vivoryon Therapeutics NV's ROE % Adjusted to Book Value of -19.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Vivoryon Therapeutics NV and its competitors. Vivoryon Therapeutics NV's current ROE % Adjusted to Book Value is -19.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivoryon Therapeutics NV stock overvalued right now?
Vivoryon Therapeutics NV (FRA:05Y) has a current ROE % Adjusted to Book Value of -19.00%. The current ROE % Adjusted to Book Value is -19.00%. Vivoryon Therapeutics NV's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Vivoryon Therapeutics NV (FRA:05Y), the current ROE % Adjusted to Book Value is -19.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vivoryon Therapeutics NV Business Description

Address Weinbergweg 22, Halle, SN, DEU, 06120
Vivoryon Therapeutics NV is a clinical-stage biopharmaceutical company focused on discovering, developing, and potentially commercializing small-molecule-based medicines that modulate the activity and stability of pathologically altered proteins. Vivoryon is currently focused on developing treatments for chronic kidney disease (CKD), and more precisely, is initially targeting stage 3b and worse diabetic kidney disease (DKD). Its product pipeline includes various drug candidates, including varoglutamstat (PQ912), VY2149, and NCE, as potential treatments for chronic kidney disease (CKD), and more precisely, are initially targeting stage 3b and worse diabetic kidney disease (DKD). The company is also pursuing antibody-based approaches for Alzheimer's disease.
38GF Score

Get the complete analysis for FRA:05Y

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.17
Price